Novo Nordisk launches Xultophy

This month (Jan 2015) Switzerland was the first country to launch Novo Nordisk’s Xultophy (IDegLira) for people with Type 2 diabetes. Xultophy is the first combination of a basal insulin (Tresiba, insulin degludec) and a GLP-1 analogue (Victoza, liraglutide). Xultophy is administered as a once-daily single injection independently of meals. It is intended for use in adults with Type 2 diabetes that are inadequately controlled with oral glucose-lowering treatments when these are used alone or together with basal insulin. For people with type 2 diabetes uncontrolled on basal insulin, Xultophy has demonstrated a significant 1.9% HbA1c reduction, mean weight loss of 2.7 kg and a low rate of hypoglycaemia (low blood sugar) comparable to insulin degludec. Novo Nordisk expects to make Xultophy available in other countries throughout Europe in 2015.

This news item first appeared in our free-to-receive online magazine. We cover diabetes news, diabetes management equipment (diabetes kit) and food news for the diabetic diet. Go to the top of this page to sign up – we just need your email address.

Open publication

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags